The agent Irinotecan is a cytostatic and belongs to the therapeutic class of Topoisomerase I inhibitors.

ATC-Code: L01XX19


Strength is denoted by disposable cap color.

  • Irinotecan Kabi 40 mg/2 ml
  • Irinotecan Kabi 100 mg/5 ml
  • Irinotecan Kabi 300 mg/15 ml
  • Irinotecan Kabi 500 mg/25 ml


Irinotecan Kabi is indicated for the treatment of patients with advanced colorectal cancer:

  • In combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for advanced disease
  • As a single agent in patients who have failed an established 5-fluorouracil containing treatment regimen

Product Information

​Please note that this product may not be available in all countries due to different registration status.

Additionally, approved indications, contraindications, side effects, warnings and all over product characteristics may differ between countries. Therefore, always the text of the nationally registered and approved product information is binding! Furthermore, country specific regulatory considerations affect the information we can provide on our products.

If you require any information please contact your local organization.